Position Statement: Minimal criteria for reporting veterinary and animal medicine research for mesenchymal stromal/stem cells in orthopaedic applications. (2022)
Journal Article
Guest, D. J., Dudhia, J., Smith, R. K., Roberts, S., Conzemius, M., Innes, J. F., …Meeson, R. L. (2022). Position Statement: Minimal criteria for reporting veterinary and animal medicine research for mesenchymal stromal/stem cells in orthopaedic applications. Frontiers in Veterinary Science, https://doi.org/10.3389/fvets.2022.817041

Mesenchymal stromal/stem cells (MSCs) are being used in an increasingly broad range of clinical applications in horses, dogs and cats. In this position statement, we aim to provide guidelines to improve reporting research involving the use of MSCs in... Read More about Position Statement: Minimal criteria for reporting veterinary and animal medicine research for mesenchymal stromal/stem cells in orthopaedic applications..

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells (2020)
Journal Article
Shah, M., Maroof, A., Gikas, P., Mittal, G., Keen, R., Baeten, D., …Roberts, S. J. (2020). Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open, 6(2), e001306. https://doi.org/10.1136/rmdopen-2020-001306

Objectives Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understo... Read More about Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.